We are live on ! Find out more
GALTW

Galectin Therapeutics Inc. - Warrants
GALTW

Delisted

GALTW was delisted on the 23rd of March, 2017.

Back to rankings

4 hedge funds and large institutions have $42K invested in Galectin Therapeutics Inc. - Warrants in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less funds holding

Funds holding: 5 → 4 (-1)

66% less capital invested

Capital invested by funds: $123K → $42K (-$81K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2K
2
UBS Group
UBS Group
Switzerland
-$67
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$35K – – –
Neuberger Berman Group
2
Neuberger Berman Group
New York
$7K – – –
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
– -$2K -15,450 Closed
UBS Group
4
UBS Group
Switzerland
– -$67 -800 -27%

GALTW Hedge Fund Activity: Q4 2016 in Review

4 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics Inc. - Warrants (GALTW) for Q4 2016, worth a combined $42K — down 66% from $123K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GALTW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $2K sold.

  • 4 institutional investors held Galectin Therapeutics Inc. - Warrants (GALTW) as of Q4 2016, down from 5 in Q3 2016.
  • Funds reported $42K of Galectin Therapeutics Inc. - Warrants stock for Q4 2016, down 66% quarter-over-quarter.
  • 0 funds opened new Galectin Therapeutics Inc. - Warrants positions in Q4 2016 and 1 closed out, a net change of -1 holder.
  • The largest Galectin Therapeutics Inc. - Warrants seller in Q4 2016 was Susquehanna International Group, an estimated $2K sold.

Based on aggregated 13F filings for Q4 2016.